


SynBio for the Environment



Víctor de Lorenzo

<http://www.cnb.csic.es/~meml>

Centro Nacional de Biotecnología (CNB)

Consejo Superior de Investigaciones Científicas (CSIC)



Madrid (Spain)










Our scenario ...







Accessing the catabolic landscape


Repsol - YPF Oil Refinery. Puertollano (Spain)





CH₃
(CH)_n
CH₃





Recalcitrance

Mineralization



CO₂
+
H₂O

Biotransformation
Co-metabolism

Biotransformation
N, S, electron acceptor

Engineered Biological agents for environmental application

- *In situ* biodegradation
- Bio-transformation
- Detection
- Immobilization

Physics, Computation and Engineering

From servants to Masters of the (biotech) House?

Service

Molecular Biology

(hypothesis-driven experimentation)

Partnership

Systems Biology

(data-driven information mining;
model-driven experimentation)

Leadership?


Synthetic Biology

(forward design of biological properties)

Proposition #1

The criterion for identifying new scenarios associated to the application of Synthetic Biosystems is not the way the agent is engineered, but the divide between familiar and non-familiar Biology.

The roadmap from Genetic Engineering to Synthetic/Non-natural MO



E. coli Nissle 1917




MUTAFLOR[®]

Wirkstoff: E. coli Stamm Nissle 1917



Zusammensetzung:

1 magensaftresistente Hartkapsel
enthält: Escherichia coli Stamm
Nissle 1917 entsprechend $2,5 - 25 \times 10^9$
vermehrungsfähigen Zellen (KBE)




- Orthogonal ribosomes
- Alternative/expanded genetic codes
- Proteins with non-natural amino acids


Streamlined genome




Xeno-Nucleic acids (XNAs)




Vesicles/artificial cells




Non-familiar Biology




Alternative information-bearing molecules / genomes



Orthogonal cells






The 10 questions on environmental risks borne by Engineered/synthetic/non-natural microorganisms (SEMs)

1. Can SEMs colonize and eventually takeover natural microbial communities?
2. Is there a chance that SEMs enter new niches that natural bacteria cannot?
3. Might SEMs go into a stage of uncontrolled growth?
4. What are the chances of horizontal transfer of the synthetic genes to novel recipients?
5. Is there a tradeoff between safety and biotechnological efficacy of SEMs?
6. Could traits engineered in SEMs evolve towards virulence or other deleterious behavior?
7. Are there scenarios of SEMs capable of damaging life or property?
8. What is the environmental fate of synthetic genes?
9. Are there chances of malicious misuse of SEMs
10. Should SEMs be endowed with traits to increase their safety and predictability?

Proposition #2

The biggest challenge of SB re. Environmental applications is the projection of stochastic behaviour of individuals into population performance.

Projection of stochastic-single cell events into population behaviour



The Complexity Pyramid

Experimental Approaches

Process Analysis


Activities, Microprobes

Community Profiling, Tracer Technology

Metabolic networks

Transcriptomics, Proteomics, Metabolomics, Phenotype

Genetics, Genomics



Biological questions

Global Processes, Interactions

Local Interactions

Community Dynamics, Activities, Invasions

Metabolic Networks And Interactions


Cellular Activities

Gene expression, Regulation

Proposition #3

For the next 10 year (at least),
frontline Environmental Biotech
research will rely the combination of
Metagenomics with Synthetic
Biology.


Combining Synthetic Biology with Metagenomics




Proposition #4

Synthetic Biology will bring about a transition from a Geno-centric Environmental Biotech to a Chemo-centric discipline


The geno-centric syndrome




The geno-centric syndrome



The ongoing shift in understanding live systems



The selfish metabolism




Proposition #5

Address public debates with a historical perspective:

- Learn from past controversies
- Study mistakes and try better
- Do not alarm the public
- Find societal allies

Boston 1846

William Morton



Questions raised by every new groundbreaking Technology related to Life Sciences

- What is the Science behind?
- Is it safe? ¿Risks?
- Who owns intellectual property?
- Who benefits?
- Should it be regulated / controlled? By whom?
- Natural vs. Non-natural: Are we playing God?

and by all means...

Do not play the arsonist fireman!


Nature **224**, 768-774 (22 November 1969)
Received 18 September 1969

Isolation of Pure *lac* Operon DNA*

JIM SHAPIRO, LORNE MACHATTIE[†], LARRY
ERON, GARRET IHLER[‡], KARIN IPPEN[§] &
JON BECKWITH

1. Department of Bacteriology and Immunology, and Department of Biological Chemistry, Harvard Medical School, Boston, Massachusetts 02115
2. Present addresses: [†]Department of Cell Biology, University of Toronto, Ontario.
3. [‡]Department of Biochemistry, University of Pittsburgh, Pittsburgh, Pennsylvania.
4. [§]MRC Microbial Genetics Research Unit, Department of Molecular Biology, University of Edinburgh, West Mains Road, Edinburgh.

Two specialized transducing phages, which carry the *lac* operon of *Escherichia coli* inserted into their DNA in opposite orientations, are used as a source of complementary sequences from which to prepare pure *lac* operon duplex. The availability of a single pure promoter will facilitate many new experiments on genetic transcription.





Paris, 1800



Knoxville, 1990

Centro Nacional de Biotecnología (CNB)


Consejo Superior de Investigaciones Científicas (CSIC)




Madrid-Cantoblanco (Spain)

Proposition #5

Think BIG! For the first time we can entertain scenarios for engineering global biocatalysis interventions



SIZE MATTERS




Proposition #6

Look at societal/ethical debates with a historical perspective – do not re-invent the wheel by over-emphasizing issues that were tackled time ago

Boston 1846

William Morton



Questions raised by every new groundbreaking Technology related to Life Sciences

- What is the Science behind?
- Is it safe? ¿Risks?
- Who owns intellectual property?
- Who benefits?
- Should it be regulated / controlled? By whom?
- Natural vs. Non-natural: Are we playing God?



Proposition #7

Pursue societal allies and identify end-users beyond lobbying/impressing/entertaining the powerful



Paris, 1800



Knoxville, 1990

This paper was produced for a meeting organized Health & Consumers DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumers DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.